Int Forum Allergy Rhinol:囊性纤维化慢性鼻窦炎的严重度临床预测因子研究

2019-06-22 AlexYang MedSci原创

慢性鼻窦炎(CRS)是一种囊性纤维化(CF)的显著表现,并且症状广泛,疾病严重度也不一。最近,有研究人员确定了与疾病严重度结果相关的一些临床变量.研究包括了33名CF-CRS患者,平均跟踪调查的时间为15个月。在研究期间,鼻炎发作患者比例为61%,并且女性患者恶化的风险增加。二次就诊时,肺部恶化与窦性恶化的让步比为2.07。另外,CF相关的糖尿病与更差的症状和内窥镜情况相关。金黄色葡萄球菌感染能够

慢性鼻窦炎(CRS)是一种囊性纤维化(CF)的显著表现,并且症状广泛,疾病严重度也不一。最近,有研究人员确定了与疾病严重度结果相关的一些临床变量.

研究包括了33名CF-CRS患者,平均跟踪调查的时间为15个月。在研究期间,鼻炎发作患者比例为61%,并且女性患者恶化的风险增加。二次就诊时,肺部恶化与窦性恶化的让步比为2.07。另外,CF相关的糖尿病与更差的症状和内窥镜情况相关。金黄色葡萄球菌感染能够预测更差的症状,然而绿脓假单胞菌能够改善症状。研究还发现,过敏性鼻炎与更差的内镜表现相关,鼻类固醇的使用与鼻内镜表现的改善有关。

最后,研究人员指出,性别、CF相关的糖尿病、鼻窦感染状态、过敏性鼻炎和鼻类固醇使用都能够调节成年人CF-CRS的严重度。窦性恶化也许是肺部恶化的一个前兆。

原始出处:

Zemke AC, Nouraie SM, Moore J et al. Clinical predictors of cystic fibrosis chronic rhinosinusitis severity. Int Forum Allergy Rhinol. 04 Jun 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675904, encodeId=c91116e5904fb, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Mar 29 13:03:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634134, encodeId=05e3163413487, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Sat Feb 08 07:03:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310730, encodeId=e3b21310e30c8, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329251, encodeId=fd32132925180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351400, encodeId=a87d13514002c, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2020-03-29 wolongzxh
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675904, encodeId=c91116e5904fb, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Mar 29 13:03:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634134, encodeId=05e3163413487, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Sat Feb 08 07:03:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310730, encodeId=e3b21310e30c8, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329251, encodeId=fd32132925180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351400, encodeId=a87d13514002c, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1675904, encodeId=c91116e5904fb, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Mar 29 13:03:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634134, encodeId=05e3163413487, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Sat Feb 08 07:03:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310730, encodeId=e3b21310e30c8, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329251, encodeId=fd32132925180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351400, encodeId=a87d13514002c, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1675904, encodeId=c91116e5904fb, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Mar 29 13:03:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634134, encodeId=05e3163413487, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Sat Feb 08 07:03:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310730, encodeId=e3b21310e30c8, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329251, encodeId=fd32132925180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351400, encodeId=a87d13514002c, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2019-06-24 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1675904, encodeId=c91116e5904fb, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Mar 29 13:03:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634134, encodeId=05e3163413487, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Sat Feb 08 07:03:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310730, encodeId=e3b21310e30c8, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329251, encodeId=fd32132925180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351400, encodeId=a87d13514002c, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 24 09:03:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]

相关资讯

PLoS One:过敏性鼻炎儿科患者的急性鼻窦炎群体研究

虽然慢性鼻窦炎是过敏性鼻炎的常见并发症,而急性鼻窦炎与过敏性鼻炎之间的联系不清楚。最近,有研究人员利用基于群体的健康研究数据评估了患有过敏性鼻炎儿科患者的急性鼻窦炎发生率。研究包括了新诊断的年龄在5-18岁的过敏性鼻炎患者,并通过性别、年龄和年份指数匹配构建了一个比较群体。研究人员对所有的患者进行了跟踪调查,直到急性鼻窦炎诊断或者跟踪调查结束为止,并利用Cox比例风险模型评估了过敏性鼻炎和急性鼻窦

Am J Rhinol Allergy:基于哮喘和过敏性鼻炎并发的慢性鼻窦炎表型的组织病理学内皮分型分析

根据表型和内皮分型,临床研究中越来越倾向于改善慢性鼻窦炎(CRS)的特性。最近,有研究人员利用组织病理学标记对支气管哮喘(BA)和过敏性鼻炎并发或有或无情况下的CRS表型进行了鉴定。研究是一个前瞻性的案例对照研究,包括了82名参与者。其中67名为CRS患者,15名为对照。研究发现,在具有AR或BA以及均有的CRS患者中,与对照组相比,嗜酸性粒细胞的比例显著增加(p<0.001)。相反,不具有

FDA批准了优先审查赛诺菲的白细胞介素-4单抗Dupixent治疗鼻窦炎

Dupilumab是一种完全人源性抗白细胞介素-4受体α单克隆抗体,可阻断白细胞介素-4和白细胞介素-13的信号传导,可以减轻2型炎症。该药物获得优先审查是基于两项关键性III期试验数据的支持,这些试验评估了Dupixent与标准治疗药物皮质类固醇鼻喷雾剂联合使用时的疗效和安全性。

J Allergy Clin Immunol:鼻息肉慢性鼻窦炎患者中免疫球蛋白G能够调控促炎性lgE响应

鼻息肉慢性鼻窦炎(CRSwNP)通常可以通过多克隆lgE个体基因型的局部产生来鉴定。虽然组织lgE浓度能够达到几千kU/L,鼻息肉中lgE调节的炎症是通过怎样的机制来调控的仍旧不清楚。最近,有研究人员探索了是否鼻息肉中局部诱导的lgG抗体能够抑制lgE调节的促炎性响应。研究人员从草花粉过敏的CRSwNP和非过敏性对照受试者中采集了鼻息肉匀浆。研究发现,鼻息肉中,lgG在控制lgE调节的炎症响应方面

J Clin Med:肖格伦综合征与慢性鼻窦炎患者的相关性分析

最近,有研究人员调查了慢性鼻窦炎(CRS)风险在肖格伦综合征(SS)患者中的情况。研究包括了18723名患有SS的患者,时间为1997年和2011之间。更多的是,59568名不患有SS的患者与患有SS的患者在性别、年龄、城市化水平、收入水平和鼻炎并发症以及鼻中隔偏曲匹配的比例为1:4。主要结果为CRS的发生率。研究发现,CRS在患有SS的患者中的累积发生率要比那些没有患SS的患者显著更高(p<